Learn More
UNLABELLED Previous trials investigating the efficacy of treatment durations shorter than the standard of 24 weeks for chronic hepatitis C virus (HCV) genotype 2/3 infections have yielded discordant results. The aims of this investigator-initiated phase III study were to compare the efficacy of 12 or 24 weeks of treatment and to identify patients suitable(More)
Background. @nbsp; Cerebrovascular complications (CVCs) have remained a major therapeutic and prognostic challenge associated with infective endocarditis, and definite risk factors have not been fully elucidated. This prospective study was designed to the evaluate the total incidence of CVC associated with infective endocarditis and major risk factors.(More)
UNLABELLED High systemic levels of interferon-gamma-inducible protein 10 kDa (IP-10) at onset of combination therapy for chronic hepatitis C virus (HCV) infection predict poor outcome, but details regarding the impact of IP-10 on the reduction of HCV RNA during therapy remain unclear. In the present study, we correlated pretreatment levels of IP-10 in liver(More)
OBJECTIVE The results of a previous study suggest that an index calculated according to the formula (normalized ASAT x PK-INR) x 100/thrombocyte count (x 10(9)/L; GUCI) may reflect liver fibrosis in patients with chronic hepatitis C virus (HCV) infection. The aims of the present study were (i) to validate the association between the Göteborg University(More)
In hepatitis C virus (HCV) genotype 1 infection, the likelihood of obtaining sustained virological response (SVR) is associated with higher ribavirin exposure. Such an association has not been demonstrated for HCV genotype 2/3 infection, where a fixed 800 mg daily dosing of ribavirin is generally recommended. The primary aim of this study was to investigate(More)
Twelve of 303 per-protocol patients were nonresponders in a 12-week versus 24-week treatment study of hepatitis C virus (HCV) genotype 2/3 infection. The nonresponders had significantly lower interferon concentrations, as well as significantly greater mean age, body mass index, and viral load. Suboptimal drug concentrations may thus contribute to lack of(More)
Dalgard andMangia address an important issue in the treatment of infections with hepatitis C virus (HCV) genotype 2/3, that is, the putative benefit of adjusting the ribavirin dose for weight rather than, as in our NORDynamIC trial, using a fixed dose. The authors specifically point to a higher relapse rate in patients receiving short-term pegylated(More)
BACKGROUND AND AIMS Recently, several genome-wide association studies have revealed that single nucleotide polymorphisms (SNPs) in proximity to IL28B predict spontaneous clearance of HCV infection as well as outcome following peginterferon and ribavirin therapy among HCV genotype 1 infected patients. The present study aimed to evaluate the impact of IL28B(More)
We read with interest the article by Sonneveld et al., who reported an association between on-treatment hepatitis B surface antigen (HBsAg) levels and a sustained response to peginterferon alfa-2b in hepatitis B e antigen (HBeAg)–positive patients (n 1⁄4 221). No HBsAg decline by week 12 of therapy was associated with a low chance of a sustained response(More)
BACKGROUND Following the discovery of the hepatitis C virus (HCV) in 1989, screening of all blood donors for antibodies became mandatory in Sweden as of 1 January 1992. METHODS Serum samples were collected from patients who had received a blood transfusion in the period prior to 1992 in western Sweden. The prevalence of HCV infection was assessed by(More)